Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.
For many years, the gold standard cancer grading and staging had focused on the characteristics of the cancer cells and often disregarded the non-tumoral cell compartments. The expansion of research on the tumor immune microenvironment, the successes and dissemination of immunotherapies to treat can...
| Publicado en: | Virchows Archiv: European Journal of Pathology Vol. 474; no. 4; pp. 463 - 475 |
|---|---|
| Autores principales: | , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Apr2019
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=135715963&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 135715963 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09456317 O1Z jtl: Virchows Archiv: European Journal of Pathology issn: 09456317 maglogo: N pubinfo: dt: Apr2019 vid: 474 iid: 4 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 135715963 135715963 NLM30631935 135715963 10.1007/s00428-018-02517-1 NLM30631935 135715963 ppf: 463 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. aug: au: Giraldo, Nicolas A. Peske, J. David Sautès-Fridman, Catherine Fridman, Wolf H. affil: Pathology Department, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, 21287, Baltimore, MD, USA sug: subj: Oncology Trends Neoplasms Classification Oncology Methods Human Cell Physiology Immunology Neoplasms Pathology Neoplasms Immunology ab: For many years, the gold standard cancer grading and staging had focused on the characteristics of the cancer cells and often disregarded the non-tumoral cell compartments. The expansion of research on the tumor immune microenvironment, the successes and dissemination of immunotherapies to treat cancer, and the open access to large -omic databases have allowed the development of novel powerful immune-based prognostic and theranostic biomarkers. Although they often correlate with histopathologic characteristics and TNM staging, in many instances, they are independently associated with, and potentially superior predictors of, the patient's prognosis and response to immunotherapies. As pathologists in the era of precision medicine, we are uniquely positioned to participate in the integration of these histologic and molecular features of the tumor microenvironment to provide the best prognostic information to clinicians and patients. In this review, we summarize some of the most important immune-related prognostic biomarkers in solid cancer, how they integrate with traditional histopathologic (i.e., staging and grading) and novel molecular stratification systems, and their potential role as predictors to response to agents blocking the PD-1/PD-L1 axis. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|